Citrini: AI Investment Overcrowded, Suggests Watch for 5 Major Blind Spot Opportunities
BlockBeats News, June 27th - Citrini Research, the organization behind the "AI Doomsday Report," released a new research report stating that despite the AI hype bringing up discussions on data centers, computing power, and electricity bottlenecks, it has become overcrowded. A large amount of intellectual and model resources have been focused on a single AI narrative, leading to other areas being under-allocated, under-modeled, and neglected, which could trigger a rotation of funds to forgotten topics.
The article lists five specific themes and suggests that investors pay attention to opportunities in the life science cycle, high-end residential/retirement housing, the fintech renaissance, airlines, and other areas that have been mistakenly killed.
Citrini Research, a research organization with significant market influence, previously issued a report in February of this year introducing the concept of a "global intelligence crisis," warning that AI could lead to a "race to the bottom" for knowledge-based jobs, disrupting the industry and credit chain built around white-collar productivity. This report subsequently caused a sharp drop in the US stock market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

The 160 Threshold Under Threat Again! Yen Nears "Intervention Red Line," Tokyo May Spend Money Again to Rescue the Currency
The Japanese yen is approaching the 1 USD = 160 JPY level. Atsushi Mimura commented that the movement is "too fast." The US-Japan interest rate gap may widen further, and Japanese officials have hinted at being ready to intervene again.
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
